摘要
本月全球药品研发进展取得成效的药物有42个,比上月增加了12个,进入注册和注册前阶段的药品数量有大幅增加,而进入Ⅲ期临床阶段的药品数量均略有减少。
出处
《中国医药工业杂志》
CAS
CSCD
北大核心
2007年第1期I0013-I0016,共4页
Chinese Journal of Pharmaceuticals
同被引文献21
-
1纳米技术用于给药系统研究进展不断[J].中国医药技术与市场,2007,7(4):61-61. 被引量:1
-
2Keating GM,Croom KF.Fenofibrate:A review of its use in primary dyslipidaemia,the metabolic syndrome and type 2 diabetes mellitus[J].Drugs,2007,67(1):121-153.
-
3Fournier Innovation et Synergie.Novel dosage form of fenofibrate[P].US:4895726,1990-01-23.
-
4Guichard JP,Blouquin P,Qing Y.A new formulation of fenofibrate:Suprabioavailable tablets[J].Current Medical Research and Opinion,2000,16(2):134-138.
-
5Shegokar R,Moller RE Nanocrystals:Industrially feasible multifunctional formulation technology for poorly soluble actives[J].Int J Pharm,2010,399(1-2):129-139.
-
6Mochalin VN,Sagar A,Gour S,et al.Manufacturingnanosized fenofibrate by salt assisted milling[J].Pharm Res,2009,26(6):1365-1370.
-
7Srinarong P,Faber JH,Visser MR,et al.Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants[J].Eur J Pharm Biopharm,2009,73(1):154-161.
-
8Patel T,Pate LD,Patel T,et al.Enhancement of dissolution of Fenofibrate by solid dispersion technique[J].Int J Res Pharm Sci,2010,1(2):127-132.
-
9He H,Yang R,Tang X.In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion[J].Drug Dev Ind Pharm,2010,36(6):681-687.
-
10Krayz GT,Averbuch M,Berman A,et al.Oral delivery with novel solid dispersions:Stable self-assembled formulations of lipophilic drugs with improved bioperformance[J].Drug Deliv Tec,2009,9(7):36-43.
二级引证文献20
-
1白云,宋晓峰,马勇.非诺贝特胶囊治疗高脂血症的不良反应分析[J].西南国防医药,2013,23(12):1329-1330. 被引量:3
-
2郭庆明,张晖,苏晓峰,陈宝来,萧伟.HPLC法测定非诺贝特缓释片中非诺贝特[J].现代药物与临床,2014,29(5):497-499.
-
3林丽琴,靖雅,石云峰.GC测定非诺贝特制剂中十二烷基硫酸钠含量[J].中国现代应用药学,2018,35(11):1649-1651. 被引量:4
-
4戚燕,王春艳,吴松.HPLC法测定非诺贝特软胶囊中维生素E的含量[J].中国药品标准,2014,15(5):341-343. 被引量:3
-
5舒欣,王明浩,杨晖,黄春玉,谢俊,周建平.流化床混悬液上药法制备非诺贝特速释微丸的工艺研究[J].药学与临床研究,2015,23(1):23-26. 被引量:1
-
6姚楠,崔井朝,孙冬梅,陈玉兴,曾晓会,赵自明.非诺贝特对酿酒酵母基因表达谱影响的研究[J].按摩与康复医学,2015,6(14):76-78.
-
7洪丽萍,黄加秀,蔡亚兰,宗艳艳,谢春娟.HPLC测定清洁验证残留物非诺贝特的含量[J].中国执业药师,2015,12(8):28-31. 被引量:3
-
8姜玲海,张军,方忠宏,周泉.药源性横纹肌溶解症高危因素研究[J].中国药房,2015,26(29):4082-4086. 被引量:15
-
9傅行弟.熔融法制备非诺贝特缓释胶囊的处方工艺研究[J].安徽医药,2016,20(5):852-855. 被引量:1
-
10徐冀文,王红爱,李曼.HPLC法测定非诺贝特胶囊中非诺贝特的含量[J].中国药师,2016,19(7):1423-1424. 被引量:1
-
1全球药品研发进展(2006.6)[J].中国医药工业杂志,2006,37(12).
-
2(Pharmaceutical Industry Information Center, Shanghai Institute of Pharmaceutical Industry, Shanghai 200040).全球药品研发进展(2007.07)[J].中国医药工业杂志,2008,39(2):158-160.
-
3全球药品研发进展(2006.03)[J].中国医药工业杂志,2006,37(9).
-
4全球药品研发进展(2006.12)[J].中国医药工业杂志,2007,38(7).
-
5全球药品研发进展[J].中国医药工业杂志,2007,38(5).
-
6(Pharmaceutical Industry Information Center, Shanghai Institute of Pharmaceutical Industry, Shanghai 200040).全球药品研发进展(2007.06)[J].中国医药工业杂志,2008,39(1):73-75.
-
7全球药品研发进展[J].中国医药工业杂志,2007,38(12).
-
8(Pharmaceutical Industry Information Center,Shanghai Institute of Pharmaceutical Industry,Shanghai 200040).全球药品研发进展(2007.08)[J].中国医药工业杂志,2008,39(3):238-240.
-
9全球药品研发进展(2007.4)[J].中国医药工业杂志,2007,38(11).
-
10全球药品研发进展(2006.5)[J].中国医药工业杂志,2006,37(11).